NASDAQ:PLRX

Pliant Therapeutics Competitors

$29.93
-0.71 (-2.32 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.89
Now: $29.93
$30.41
50-Day Range
$30.23
MA: $36.29
$40.23
52-Week Range
$19.42
Now: $29.93
$43.92
Volume65,271 shs
Average Volume168,654 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pliant Therapeutics (NASDAQ:PLRX) Vs. HCM, EBS, IMAB, ARNA, AGIO, and AVIR

Should you be buying PLRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Pliant Therapeutics, including Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), I-Mab (IMAB), Arena Pharmaceuticals (ARNA), Agios Pharmaceuticals (AGIO), and Atea Pharmaceuticals (AVIR).

Hutchison China MediTech (NASDAQ:HCM) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Hutchison China MediTech and Pliant Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Pliant Therapeutics20.83%16.55%8.33%

Insider & Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 79.5% of Pliant Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Hutchison China MediTech and Pliant Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Pliant Therapeutics00503.00

Hutchison China MediTech presently has a consensus target price of $40.00, indicating a potential upside of 36.75%. Pliant Therapeutics has a consensus target price of $45.50, indicating a potential upside of 52.02%. Given Pliant Therapeutics' higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Hutchison China MediTech.

Earnings & Valuation

This table compares Hutchison China MediTech and Pliant Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.79$-106,020,000.00($0.80)-36.56
Pliant Therapeutics$57.05 million18.75$-630,000.00N/AN/A

Pliant Therapeutics has lower revenue, but higher earnings than Hutchison China MediTech.

Summary

Pliant Therapeutics beats Hutchison China MediTech on 7 of the 9 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pliant Therapeutics20.83%16.55%8.33%
Emergent BioSolutions12.50%26.68%12.70%

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Pliant Therapeutics and Emergent BioSolutions, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pliant Therapeutics00503.00
Emergent BioSolutions02502.71

Pliant Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 52.02%. Emergent BioSolutions has a consensus target price of $113.6667, indicating a potential upside of 46.40%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Emergent BioSolutions.

Valuation and Earnings

This table compares Pliant Therapeutics and Emergent BioSolutions' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$57.05 million18.75$-630,000.00N/AN/A
Emergent BioSolutions$1.11 billion3.76$54.50 million$2.9126.68

Emergent BioSolutions has higher revenue and earnings than Pliant Therapeutics.

Summary

Emergent BioSolutions beats Pliant Therapeutics on 6 of the 10 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pliant Therapeutics20.83%16.55%8.33%
I-MabN/AN/AN/A

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of I-Mab shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Pliant Therapeutics and I-Mab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pliant Therapeutics00503.00
I-Mab00403.00

Pliant Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 52.02%. I-Mab has a consensus target price of $70.00, indicating a potential upside of 22.81%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than I-Mab.

Valuation and Earnings

This table compares Pliant Therapeutics and I-Mab's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$57.05 million18.75$-630,000.00N/AN/A
I-Mab$4.31 million951.50$-208,560,000.00($28.90)-1.97

Pliant Therapeutics has higher revenue and earnings than I-Mab.

Summary

Pliant Therapeutics beats I-Mab on 8 of the 9 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pliant Therapeutics20.83%16.55%8.33%
Arena PharmaceuticalsN/A-33.17%-30.41%

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Pliant Therapeutics and Arena Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pliant Therapeutics00503.00
Arena Pharmaceuticals001503.00

Pliant Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 52.02%. Arena Pharmaceuticals has a consensus target price of $92.80, indicating a potential upside of 40.82%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Arena Pharmaceuticals.

Valuation and Earnings

This table compares Pliant Therapeutics and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$57.05 million18.75$-630,000.00N/AN/A
Arena Pharmaceuticals$806.43 million4.93$397.55 million$7.698.57

Arena Pharmaceuticals has higher revenue and earnings than Pliant Therapeutics.

Pliant Therapeutics (NASDAQ:PLRX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pliant Therapeutics20.83%16.55%8.33%
Agios Pharmaceuticals-170.65%-57.63%-37.15%

Insider and Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are owned by institutional investors. 3.2% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pliant Therapeutics and Agios Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pliant Therapeutics00503.00
Agios Pharmaceuticals03702.70

Pliant Therapeutics currently has a consensus price target of $45.50, suggesting a potential upside of 52.02%. Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 18.19%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than Agios Pharmaceuticals.

Earnings & Valuation

This table compares Pliant Therapeutics and Agios Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$57.05 million18.75$-630,000.00N/AN/A
Agios Pharmaceuticals$117.91 million32.38$-411,470,000.00($6.86)-7.97

Pliant Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals.

Summary

Pliant Therapeutics beats Agios Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Pliant Therapeutics (NASDAQ:PLRX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Pliant Therapeutics and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pliant Therapeutics20.83%16.55%8.33%
Atea PharmaceuticalsN/AN/AN/A

Insider and Institutional Ownership

79.5% of Pliant Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pliant Therapeutics and Atea Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pliant Therapeutics00503.00
Atea Pharmaceuticals00403.00

Pliant Therapeutics currently has a consensus price target of $45.50, suggesting a potential upside of 52.02%. Atea Pharmaceuticals has a consensus price target of $69.3333, suggesting a potential upside of 54.28%. Given Atea Pharmaceuticals' higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Pliant Therapeutics.

Earnings & Valuation

This table compares Pliant Therapeutics and Atea Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$57.05 million18.75$-630,000.00N/AN/A
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Atea Pharmaceuticals has lower revenue, but higher earnings than Pliant Therapeutics.

Summary

Pliant Therapeutics beats Atea Pharmaceuticals on 6 of the 7 factors compared between the two stocks.


Pliant Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25-0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59-0.8%$3.42 billion$306.98 million-6.95News Coverage
Insmed logo
INSM
Insmed
1.2$33.07-1.7%$3.42 billion$136.47 million-12.72News Coverage
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15-0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.65-2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46-5.3%$2.75 billion$260.98 million-357.67Analyst Downgrade
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00-0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39-0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Gap Down
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26-5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73-0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91Gap Down
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13-5.6%$2.35 billion$15 million-17.35Unusual Options Activity
News Coverage
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15-0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44-1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02-0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22-3.5%$1.94 billion$410,000.00-5.92Analyst Report
Gap Down
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69-4.6%$1.91 billionN/A-25.40Increase in Short Interest
News Coverage
Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$31.83-2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Gap Down
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73-3.2%$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59-3.1%$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91-3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.